2015 Fiscal Year Final Research Report
Wilms tumor 1 peptide vaccination against relapseed or recurrence glioblastoma: safety and impact on immunological response
| Project/Area Number |
26860797
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Keywords | 悪性神経膠腫 / 免疫療法 |
|---|
| Outline of Final Research Achievements |
Result of our department was transferred to company and it induced the clinical trial by company. So we studied the expression of PD-1 on the lymphocyte of these patients, and the proportion of the regulatory T cells in these patients. We clarified the high expression of PD-1 was found on lymphocytes of patients with relapse. These findings suggested that the immunocombined therapy consisting with WT1 and immunocheckpoint inhibitors is hopeful treatment for these patient with very intractable of brain tumor.
|
| Free Research Field |
小児腫瘍
|
